FDASIA Title VII Drug Supply Chain Provisions

The globalization of the pharmaceutical market has created tremendous challenges for the U.S. Food and Drug Administration (FDA), including dramatic increases in drug imports, complex and fragmented global supply chains and increasing threats of fraudulent and substandard drugs. Title VII of the Food and Drug Administration Safety and Innovation Act (FDASIA) (Pub. L. 112-144) gives FDA new authorities to address these challenges and better ensure the safety, effectiveness and quality of drugs imported into the United States.

Implementation of these authorities will significantly advance the globalization strategies set forth in FDA’s Pathway to Global Product Safety and Quality report and support FDA's ongoing quality-related initiatives. These authorities will allow FDA to collect and analyze data to make risk-informed decisions, advance its risk-based approach to facility oversight, strengthen its partnerships with foreign regulators, and drive safety and quality throughout the supply chain through strengthened tools. At the same time, implementation of Title VII of FDASIA is difficult and complex, and requires not only the development of new regulations, guidances and reports, but also major changes in FDA information systems, processes and policies.

FDA is working diligently through this challenging implementation, prioritizing its efforts to achieve the greatest public health impact and deploy its limited resources most effectively. Stakeholder input and feedback is critically important as FDA determines how best to implement these important new authorities.